title: Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia.
authors.affiliation: Department of Medical Oncology and Hematology, Princess Margaret Cancer Center , Toronto, ON , Canada.
authors.forename: Victor H
authors.initials: VH
authors.lastname: Jimenez-Zepeda
authors.forename: Donna E
authors.initials: DE
authors.lastname: Reece
authors.forename: Suzanne
authors.initials: S
authors.lastname: Trudel
authors.forename: Christine
authors.initials: C
authors.lastname: Chen
authors.forename: Rodger
authors.initials: R
authors.lastname: Tiedemann
authors.forename: Vishal
authors.initials: V
authors.lastname: Kukreti
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D003907:Dexamethasone / Q000008:administration & dosage; D006801:Humans; D000077269:Lenalidomide; D007952:Leukemia, Plasma Cell / Q000188:drug therapy* / Q000401:mortality; D016609:Neoplasms, Second Primary / Q000188:drug therapy* / Q000401:mortality; D011719:Pyrazines / Q000008:administration & dosage; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives; D016896:Treatment Outcome
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone; D000077269:Lenalidomide